GSK Swaps Cancer For Vaccines As It Sheds Legacy Products, Not R&D
This article was originally published in The Pink Sheet Daily
Complex transaction with Novartis leaves the British drug maker with a better balanced portfolio centered on vaccines, consumer health, respiratory and HIV medicines.
You may also be interested in...
GlaxoSmithKline's new CEO is assembling a "dream team" to rebuild the big pharma's R&D pipeline with an emphasis on building in oncology. Walmsley outlined her strategy at J.P. Morgan, while Oncology Therapy Area Head Axel Hoos provided more details in an interview.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.